Xilio Therapeutics, Inc.
NASDAQ:XLO
1.31 (USD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.9 | 1.847 | 1.499 | 1.065 | 0.24 |
| Gross Profit
| -1.9 | -1.847 | -1.499 | -1.065 | -0.24 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 52.136 | 59.201 | 51.188 | 43.91 | 14.256 |
| General & Administrative Expenses
| 26.997 | 29.948 | 23.856 | 10.653 | 4.771 |
| Selling & Marketing Expenses
| -1.9 | 0 | 0 | 0 | 0 |
| SG&A
| 26.997 | 29.948 | 23.856 | 10.653 | 4.771 |
| Other Expenses
| 0 | 0.927 | -0.756 | -0.656 | 1.716 |
| Operating Expenses
| 75.704 | 89.149 | 75.044 | 54.563 | 19.027 |
| Operating Income
| -79.133 | -89.149 | -75.044 | -54.563 | -19.027 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.729 | 0.927 | -0.756 | -0.656 | 1.716 |
| Income Before Tax
| -76.404 | -88.222 | -75.8 | -55.219 | -17.311 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.927 | -1.499 | 0.859 | 0.068 |
| Net Income
| -76.404 | -87.295 | -74.301 | -55.219 | -17.311 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.78 | -3.19 | -2.72 | -2.01 | -0.63 |
| EPS Diluted
| -2.78 | -3.19 | -2.72 | -2.01 | -0.63 |
| EBITDA
| -77.233 | -89.149 | -75.044 | -53.498 | -18.787 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |